New Options in the Treatment of Lipid Disorders in HIV-Infected Patients

Abstract

Since the introduction of HAART, there was a remarkably change in the natural history of HIV disease, leading to a notable extension of life expectancy, although prolonged metabolic imbalances could significantly act on the longterm prognosis and outcome of HIV-infected persons, and there is an increasing concern about the cardiovascular risk in this population. Current recommendations suggest that HIV-infected perons undergo evaluation and treatment on the basis of the Third National Cholesterol Education Program Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (NCEP ATP III) guidelines for dyslipidemia, with particular attention to potential drug interactions with antiretroviral agents and maintenance of virologic control of HIV infection. While a hypolipidemic diet and physical activity may certainly improve dyslipidemia, pharmacological treatment becomes indispensable when serum lipid are excessively high for a long time or the patient has a high cardiovascular risk, since the suspension or change of an effective antiretroviral therapy is not recommended. Moreover, the choice of a hypolipidemic drug is often a reason of concern, since expected drug-drug interactions (especially with antiretroviral agents), toxicity, intolerance, effects on concurrent HIV-related disease and decrease patient adherence to multiple pharmacological regimens must be carefully evaluated. Often the lipid goals of patients in this group are not achieved by the therapy recommended in the current lipid guidelines and in this article we describe other possibilities to treat lipid disorders in HIV-infected persons, like rosuvastatin, ezetimibe and fish oil.

Are HIV patients undertreated? Cardiovascular risk factors in HIV: results of the HIV-HEART study

“…Especially, the use of PIs is associated with an increased risk for lipid disorders. 6,25,26 This is in correspondence with our data. We found patients on PI-based ART to have higher FRS than patients on a non-PI-based ART.…”

Dyslipidaemia and dysglycaemia in HIV- infected patients on highly active anti-retroviral therapy in Kumasi Metropolis

“…The search for vaccines to protect against HIV/AID has continued to elude the science world. However, the use of highly active antiretroviral therapy (HAART) has dramatically improved the prognosis of HIV-infected individuals 1,2 .The beneficial effect of reduced risk of early death from opportunistic infections and other consequences of HIV infection, is however, reduced because other possible causes of death have replaced this beneficial effect 3 . Myocardial infarction has become a matter of particular concern.…”

Effect of Extra Virgin Olive Oil on Biomarkers of Inflammation in HIV-Infected Patients: A Randomized, Crossover, Controlled Clinical Trial

“…study group reported an association between myocardial infarction and cumulative exposure to indinavir and lopinavir/ritonavir [ 5 ]. PI may increase total cholesterol and triglyceride levels and decrease HDL-cholesterol levels as a consequence of longer action of sterol regulatory element-binding protein-1 (SREBP-1) and protein kinase C activation [ 31 ]. However, the D.A.D.…”